Wedbush lowered the firm’s price target on Kala Pharmaceuticals to $22 from $39 and keeps an Outperform rating on the shares following quarterly results. The firm notes that topline data from CHASE Phase 2b of KPI-012/PCED is now expected in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KALA:
